Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Other Non Operating Income (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Other Non Operating Income for 16 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income rose 111.86% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.1 million through Dec 2025, up 107.44% year-over-year, with the annual reading at -$89000.0 for FY2025, 99.56% up from the prior year.
  • Other Non Operating Income hit $1.5 million in Q4 2025 for Ligand Pharmaceuticals, up from $833000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $5.5 million in Q4 2021 to a low of -$33.5 million in Q2 2024.
  • Historically, Other Non Operating Income has averaged -$3.1 million across 5 years, with a median of $443000.0 in 2025.
  • Biggest five-year swings in Other Non Operating Income: surged 961.19% in 2021 and later crashed 3739.98% in 2024.
  • Year by year, Other Non Operating Income stood at $5.5 million in 2021, then plummeted by 114.38% to -$793000.0 in 2022, then crashed by 442.24% to -$4.3 million in 2023, then crashed by 190.81% to -$12.5 million in 2024, then surged by 111.86% to $1.5 million in 2025.
  • Business Quant data shows Other Non Operating Income for LGNDZ at $1.5 million in Q4 2025, $833000.0 in Q3 2025, and $1.4 million in Q2 2025.